ReviewFrontiers in endocrinology2025
Understanding the interplay between COVID-19 and diabetes: insights for the post-pandemic era.
Review in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Association of Chronic Hyperglycemia and Glycemic Variability with Mortality in COVID-19: Meta-Analysis of Cohort Studies.Medicina (Kaunas, Lithuania) · 2026Pooled it
- Glycemic variability and the short-term mortality of hospitalized patients with COVID-19: a meta-analysis.Frontiers in endocrinology · 2026Pooled it
- Three- and Nine-Month Follow-Up of Patients with COVID-19: Clinical, Functional, and Radiological Outcomes.Journal of clinical medicine · 2026Article
- Echocardiographic Findings in Saudi Adults With Type 2 Diabetes Mellitus in the Jazan Region.Cureus · 2026Article
- Skin manifestations in diabetes-what is new?Frontiers in medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The global pandemic caused by the SARS-CoV-2 virus has had a profound impact on the onset, progression, and management of diabetes, posing significant challenges to healthcare systems worldwide. This review elucidates the multifaceted impact of SARS-CoV-2 on diabetes mellitus, emphasizing the increased complexity of glycemic management in patients with SARS-CoV-2 infection following viral infection in the postpandemic era. In this study, we examined the diverse effects of the SARS-CoV-2 virus on individuals with diabetes. These effects included an elevated risk of morbidity, erratic fluctuations in blood glucose levels, the emergence of complications associated with diabetes, and the emergence of challenges related to self-management of the disease. From a mechanistic perspective, we investigated the following factors: SARS-CoV-2-mediated direct damage to islet beta cells, dysregulation of the RAAS system, impairment of islet function by oxidative stress, and the effects of the integrated stress response, stress response, and reduced adiponectin levels on insulin utilization efficiency and glucose metabolism. Furthermore, viral effects extend to diabetic complications and cardiovascular risk factors, such as coagulation abnormalities, hypertension, and lipid metabolism. This results in an exacerbation of the development of diabetic complications. This review highlights the urgent need for refined management strategies for patients with diabetes during the pandemic and in the later stages of COVID-19. Additionally, there is a need for integrated management strategies to mitigate the impact of COVID-19 on the long-term outcomes of patients with diabetes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.